Novozymes
kr 416.00Change from previous close: +0.73%Absolute change: +kr 3.00
At a glance
- Revenue growth
- +8.45%
- 2025 vs 2024
- Net income growth
- +90.84%
- 2025 vs 2024
- Net margin
- 14.0%
- 2024: 8.0%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 356 | 167 | 328 | 467 | 320 | 106 | 229 | 263 | 352 | 177 | 151 | 213 |
| Depreciation and amortization | 158 | 150 | 155 | 147 | 137 | 137 | 166 | 136 | 136 | 116 | 35.3 | 44.5 |
| Capital expenditure | -98.5 | -79.1 | -197 | -95.3 | -72.6 | -45.4 | -127 | -76.3 | -89.7 | -45.5 | -65.5 | -58.6 |
| Investing cash flow | -174 | -93.1 | -226 | -165 | -1,541 | -38.3 | -98.2 | -46.6 | -24.4 | -30.5 | -80.9 | -65.1 |
| Financing cash flow | -206 | -25.9 | -102 | -352 | 1,309 | -102 | -121 | -209 | -284 | -89.9 | -74.5 | -131 |
| Dividends paid | 0.0 | -265 | 0.0 | -140 | -262 | 0.0 | — | -125 | -125 | — | -156 | — |
| Share repurchases | 0.0 | 0.0 | 0.0 | — | -69.1 | -30.8 | — | — | — | — | — | — |
| Debt issued | 0.0 | 1,728 | 19.8 | — | 1,670 | 26.6 | 56.1 | — | 28.1 | 50.3 | 114 | — |
| Debt repaid | -158 | -1,542 | -125 | -215 | -51.7 | -113 | -182 | -92.7 | -109 | -157 | -39.2 | -132 |
| Effect of exchange rates | 5.6 | 3.8 | -5.9 | 3.2 | -9.4 | 3.5 | -3.3 | 5.3 | 4.3 | 7.0 | -3.1 | 0.5 |
| Net change in cash | -18.5 | 51.9 | -6.0 | -46.9 | 78.7 | -30.5 | 6.9 | 12.3 | 48.0 | 63.1 | -7.9 | 17.0 |
| Free cash flow | 258 | 88.0 | 132 | 372 | 248 | 61.0 | 102 | 186 | 262 | 131 | 85.1 | 154 |
| Levered free cash flow | 152 | 105 | 141 | 289 | 238 | 63.6 | — | — | — | — | 96.4 | 111 |